Kyverna Therapeutics (KYTX) Competitors $7.18 +1.77 (+32.72%) Closing price 04:00 PM EasternExtended Trading$7.28 +0.10 (+1.39%) As of 06:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KYTX vs. PGEN, IMNM, CRON, BGM, SYRE, RAPP, SPRY, TNGX, PHAR, and IMTXShould you be buying Kyverna Therapeutics stock or one of its competitors? The main competitors of Kyverna Therapeutics include Precigen (PGEN), Immunome (IMNM), Cronos Group (CRON), BGM Group (BGM), Spyre Therapeutics (SYRE), Rapport Therapeutics (RAPP), ARS Pharmaceuticals (SPRY), Tango Therapeutics (TNGX), Pharming Group (PHAR), and Immatics (IMTX). These companies are all part of the "pharmaceutical products" industry. Kyverna Therapeutics vs. Its Competitors Precigen Immunome Cronos Group BGM Group Spyre Therapeutics Rapport Therapeutics ARS Pharmaceuticals Tango Therapeutics Pharming Group Immatics Kyverna Therapeutics (NASDAQ:KYTX) and Precigen (NASDAQ:PGEN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, media sentiment, institutional ownership, risk and dividends. Do analysts recommend KYTX or PGEN? Kyverna Therapeutics currently has a consensus price target of $17.20, suggesting a potential upside of 139.55%. Precigen has a consensus price target of $8.25, suggesting a potential upside of 156.21%. Given Precigen's higher probable upside, analysts clearly believe Precigen is more favorable than Kyverna Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kyverna Therapeutics 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.88Precigen 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the media refer more to KYTX or PGEN? In the previous week, Precigen had 2 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 4 mentions for Precigen and 2 mentions for Kyverna Therapeutics. Precigen's average media sentiment score of 0.51 beat Kyverna Therapeutics' score of 0.00 indicating that Precigen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kyverna Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Precigen 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals hold more shares of KYTX or PGEN? 18.1% of Kyverna Therapeutics shares are owned by institutional investors. Comparatively, 33.5% of Precigen shares are owned by institutional investors. 47.1% of Precigen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has higher earnings and valuation, KYTX or PGEN? Precigen has lower revenue, but higher earnings than Kyverna Therapeutics. Precigen is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKyverna Therapeutics$7.03M44.17-$127.48M-$3.68-1.95Precigen$3.92M244.76-$126.24M-$0.42-7.67 Is KYTX or PGEN more profitable? Kyverna Therapeutics has a net margin of 0.00% compared to Precigen's net margin of -2,868.66%. Kyverna Therapeutics' return on equity of -64.98% beat Precigen's return on equity.Company Net Margins Return on Equity Return on Assets Kyverna TherapeuticsN/A -64.98% -56.17% Precigen -2,868.66%-842.83%-78.98% Which has more risk & volatility, KYTX or PGEN? Kyverna Therapeutics has a beta of 3.72, meaning that its stock price is 272% more volatile than the S&P 500. Comparatively, Precigen has a beta of 1.61, meaning that its stock price is 61% more volatile than the S&P 500. SummaryKyverna Therapeutics beats Precigen on 9 of the 17 factors compared between the two stocks. Get Kyverna Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KYTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KYTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KYTX vs. The Competition Export to ExcelMetricKyverna TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$310.54M$3.37B$6.10B$10.65BDividend YieldN/A2.29%5.70%4.74%P/E Ratio-1.9521.7185.5527.59Price / Sales44.17477.39622.26138.47Price / CashN/A47.6737.7861.77Price / Book1.1610.1413.136.76Net Income-$127.48M-$52.31M$3.30B$275.88M7 Day Performance20.27%6.72%5.27%3.71%1 Month Performance84.10%15.01%9.93%10.21%1 Year Performance56.09%29.34%87.76%35.85% Kyverna Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KYTXKyverna Therapeutics1.6112 of 5 stars$7.18+32.7%$17.20+139.6%+21.6%$310.54M$7.03M-1.9596Analyst ForecastGap UpHigh Trading VolumePGENPrecigen4.5632 of 5 stars$3.63+3.4%$8.25+127.3%+289.4%$1.05B$4.34M-8.64190Analyst ForecastGap UpIMNMImmunome1.4559 of 5 stars$11.34-2.2%$23.20+104.6%+11.0%$1.01B$9.04M-3.6840Analyst ForecastGap UpCRONCronos Group1.4925 of 5 stars$2.97+12.9%N/A+19.1%$1.01B$117.61M59.40450Analyst ForecastHigh Trading VolumeBGMBGM Group0.2512 of 5 stars$9.61-5.4%N/A+32.6%$987.78M$25.10M0.00298Analyst ForecastGap UpSYRESpyre Therapeutics3.0958 of 5 stars$16.36+0.7%$54.29+231.8%-41.7%$980.91M$890K-4.8173Analyst DowngradeRAPPRapport Therapeutics3.0293 of 5 stars$27.97+5.2%$35.33+26.3%+25.7%$970.48MN/A-11.19N/AAnalyst ForecastGap UpSPRYARS Pharmaceuticals2.7551 of 5 stars$9.72-0.8%$33.17+241.2%-24.4%$968.50M$112.34M-19.8490Analyst ForecastTNGXTango Therapeutics2.2401 of 5 stars$8.44-1.1%$10.50+24.4%+4.3%$949.05M$24.30M-6.3590Analyst ForecastPHARPharming Group2.3305 of 5 stars$14.29+3.6%$30.00+109.9%+74.6%$944.82M$339.84M-109.92280Positive NewsAnalyst ForecastShort Interest ↑Gap UpIMTXImmatics2.4558 of 5 stars$7.91+2.7%$15.00+89.6%-13.9%$935.94M$168.65M-12.17260Analyst Forecast Related Companies and Tools Related Companies PGEN Alternatives IMNM Alternatives CRON Alternatives BGM Alternatives SYRE Alternatives RAPP Alternatives SPRY Alternatives TNGX Alternatives PHAR Alternatives IMTX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KYTX) was last updated on 10/8/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored"I'm risking my reputation on this"If I'm right about what's coming, this could be the most important book you'll read this yearCrypto 101 Media | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredGOLD ALERTGold has shattered records, soaring past $3,800 an ounce... But Stansberry Senior Partner Dr. David "Doc" E...Stansberry Research | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kyverna Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kyverna Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
